Insmed, Inc. (NASDAQ:INSM – Get Free Report) traded up 7.2% during mid-day trading on Tuesday . The stock traded as high as $110.50 and last traded at $111.40. 647,989 shares changed hands during trading, a decline of 75% from the average session volume of 2,571,582 shares. The stock had previously closed at $103.89.
Insmed News Roundup
Here are the key news stories impacting Insmed this week:
- Positive Sentiment: HC Wainwright raised its Q2 2026 EPS estimate for Insmed, signaling a slightly better near-term outlook for the business.
- Positive Sentiment: The firm also increased its FY2026 EPS estimate and maintained a Buy rating, reinforcing confidence in Insmed’s longer-term growth story.
- Neutral Sentiment: HC Wainwright modestly raised its Q3 2026 estimate, another incremental improvement that is supportive but not transformative.
- Neutral Sentiment: Insmed’s recent quarterly results beat revenue and earnings expectations, but the company is still posting losses and negative margins, which keeps sentiment mixed.
- Negative Sentiment: HC Wainwright lowered some longer-dated EPS estimates, including FY2027 through FY2030, suggesting the profitability ramp may be slower than previously expected.
Analysts Set New Price Targets
Several brokerages have recently commented on INSM. Morgan Stanley upgraded Insmed from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $166.00 to $212.00 in a research report on Monday, March 30th. Royal Bank Of Canada decreased their price objective on shares of Insmed from $220.00 to $205.00 and set an “outperform” rating for the company in a report on Friday. Leerink Partners increased their target price on shares of Insmed from $210.00 to $215.00 and gave the stock an “outperform” rating in a report on Tuesday, March 24th. Bank of America raised their price target on shares of Insmed from $211.00 to $213.00 and gave the stock a “buy” rating in a research report on Tuesday, March 24th. Finally, Wells Fargo & Company decreased their price target on shares of Insmed from $177.00 to $160.00 and set an “overweight” rating for the company in a report on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $211.86.
Insmed Price Performance
The company has a market capitalization of $24.38 billion, a P/E ratio of -19.58 and a beta of 0.89. The company has a quick ratio of 4.10, a current ratio of 4.47 and a debt-to-equity ratio of 0.80. The business has a 50 day simple moving average of $144.00 and a 200-day simple moving average of $164.56.
Insmed (NASDAQ:INSM – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.14. The business had revenue of $305.96 million for the quarter, compared to analysts’ expectations of $300.81 million. Insmed had a negative net margin of 144.44% and a negative return on equity of 130.11%. The company’s revenue for the quarter was up 229.7% compared to the same quarter last year. During the same quarter last year, the company earned ($1.42) EPS. Analysts predict that Insmed, Inc. will post -2.41 EPS for the current fiscal year.
Insider Transactions at Insmed
In other Insmed news, CEO William Lewis sold 10,699 shares of the business’s stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $143.97, for a total transaction of $1,540,335.03. Following the sale, the chief executive officer directly owned 301,185 shares in the company, valued at approximately $43,361,604.45. The trade was a 3.43% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Roger Adsett sold 88,060 shares of the company’s stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $164.63, for a total transaction of $14,497,317.80. Following the completion of the sale, the chief operating officer directly owned 106,810 shares of the company’s stock, valued at approximately $17,584,130.30. This represents a 45.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 161,193 shares of company stock valued at $25,462,012. 2.10% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Insmed
Several large investors have recently made changes to their positions in the business. Norges Bank bought a new stake in shares of Insmed in the 4th quarter worth approximately $506,625,000. Vanguard Group Inc. grew its position in Insmed by 13.0% in the third quarter. Vanguard Group Inc. now owns 19,935,820 shares of the biopharmaceutical company’s stock worth $2,870,957,000 after buying an additional 2,291,328 shares during the last quarter. RTW Investments LP increased its holdings in shares of Insmed by 57.0% in the fourth quarter. RTW Investments LP now owns 4,842,879 shares of the biopharmaceutical company’s stock valued at $842,855,000 after buying an additional 1,758,321 shares in the last quarter. Artisan Partners Limited Partnership boosted its stake in shares of Insmed by 49.0% during the 3rd quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock worth $711,076,000 after acquiring an additional 1,623,342 shares in the last quarter. Finally, Orbis Allan Gray Ltd bought a new stake in shares of Insmed during the 2nd quarter worth $153,389,000.
About Insmed
Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.
The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.
Featured Stories
- Five stocks we like better than Insmed
- Shake Shack Stock Gets Shaken After Earnings Miss
- On Holdings Sets Up for Marathon Rally: New Highs Are Coming
- The DRAM Shake-Up: Samsung Stumbles, Micron Chases $1000
- MP Materials Is Quietly Building a Rare Earth Powerhouse
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.
